Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Daniel Clark maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform and raises the price target from $23 to $25.
Leerink Partners analyst Daniel Clark maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform and raises the price target from $23 to $25.